-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 8, CStone Pharmaceuticals announced that it had signed a cooperation agreement with DotBio Pte.
Ltd, a biotechnology company focused on developing next-generation antibody therapies
.
Through cooperation, the two parties will jointly develop up to three first-in-class or best-in-class next-generation antibody therapies, including multifunctional antibody drugs and antibody-conjugated drugs ("ADC")
.
It is understood that this is the first cooperation project to settle in the global R&D center and industrialization base of CStone Pharmaceuticals.
CStone Pharmaceuticals will lead the design of target combinations according to the desired mechanism of action, and Dote Bio will lead the design and construction of molecules
.
The industry expects that this cooperation will provide pre-clinical drug candidates for CStone's pipeline 2.
0 strategy and further promote drug R&D and source innovation
.
On the same day, Ascent Pharmaceuticals and Pfizer also announced a clinical cooperation and drug supply agreement.
The two parties will jointly develop Ascent Pharmaceuticals’ Bcl-2 selective inhibitor lisaftoclax (APG-2575) and Pfizer’s CDK4/6 inhibitor Aiboxin® ( Piperacillil), for the treatment of recurrent, locally advanced or metastatic estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer
.
On August 4, Zai Lab and Schrödinger announced that the two parties will cooperate on research and development and commercialization of tumor DNA damage response mechanisms on a global scale
.
According to the cooperation agreement, Zai Lab will pay Schrödinger an advance payment to fund the research and development expenses shared by Schrödinger
.
After the drug candidates are selected, Zai Lab will undertake the global development, production and commercialization of the project, and Schrödinger will also be eligible for milestone payments and royalties
.
For multinational pharmaceutical companies’ brands choosing Chinese pharmaceutical companies to develop new drugs together, the industry believes that this is mainly related to the continuous expansion of my country’s pharmaceutical market and the continuous improvement of pharmaceutical companies’ innovation capabilities..
In recent years, China’s pharmaceutical industry has developed vigorously under the support of policies, and its market scale has continued to expand.
Its share in the global pharmaceutical market has reached about 11%.
The expansion of market share has made China gradually become a new emerging with great potential and vitality in the world.
The pharmaceutical market not only promotes the development of local pharmaceutical companies, but also creates a huge attraction for multinational pharmaceutical groups
.
According to ChinaBio's data, in 2020, multinational pharmaceutical groups such as Roche, Bayer, AbbVie, and Pfizer have reached a record 271 cross-border licensing cooperation agreements with Chinese pharmaceutical companies, an increase of nearly in 2019 and 2015 respectively.
50% and more than 300%
.
Judging from the current transaction situation in 2021, the cooperation between multinational giants and local pharmaceutical companies is still continuing the growth trend of 2020
.
It is worth mentioning that in addition to the continuous increase in the number of cooperation, from the perspective of the cooperation model of Chinese and foreign pharmaceutical companies, the two parties have also changed from the initial joint venture to set up factories to license cooperation around the research and development of innovative drugs, which means that local companies’ drugs Innovative research and development capabilities have also been recognized
.
The industry believes that with China’s promulgation of a series of drug approval procedures, intellectual property protection, tax reduction and exemption, and the introduction of talents, policies to encourage the promotion of the research and development, marketing and sales of innovative drugs
.
In the future, this innovative model of combining powerful forces will continue.
Affected by this, the market share of China's innovative drugs is expected to increase further
.
Ltd, a biotechnology company focused on developing next-generation antibody therapies
.
Through cooperation, the two parties will jointly develop up to three first-in-class or best-in-class next-generation antibody therapies, including multifunctional antibody drugs and antibody-conjugated drugs ("ADC")
.
It is understood that this is the first cooperation project to settle in the global R&D center and industrialization base of CStone Pharmaceuticals.
CStone Pharmaceuticals will lead the design of target combinations according to the desired mechanism of action, and Dote Bio will lead the design and construction of molecules
.
The industry expects that this cooperation will provide pre-clinical drug candidates for CStone's pipeline 2.
0 strategy and further promote drug R&D and source innovation
.
On the same day, Ascent Pharmaceuticals and Pfizer also announced a clinical cooperation and drug supply agreement.
The two parties will jointly develop Ascent Pharmaceuticals’ Bcl-2 selective inhibitor lisaftoclax (APG-2575) and Pfizer’s CDK4/6 inhibitor Aiboxin® ( Piperacillil), for the treatment of recurrent, locally advanced or metastatic estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer
.
On August 4, Zai Lab and Schrödinger announced that the two parties will cooperate on research and development and commercialization of tumor DNA damage response mechanisms on a global scale
.
According to the cooperation agreement, Zai Lab will pay Schrödinger an advance payment to fund the research and development expenses shared by Schrödinger
.
After the drug candidates are selected, Zai Lab will undertake the global development, production and commercialization of the project, and Schrödinger will also be eligible for milestone payments and royalties
.
For multinational pharmaceutical companies’ brands choosing Chinese pharmaceutical companies to develop new drugs together, the industry believes that this is mainly related to the continuous expansion of my country’s pharmaceutical market and the continuous improvement of pharmaceutical companies’ innovation capabilities..
In recent years, China’s pharmaceutical industry has developed vigorously under the support of policies, and its market scale has continued to expand.
Its share in the global pharmaceutical market has reached about 11%.
The expansion of market share has made China gradually become a new emerging with great potential and vitality in the world.
The pharmaceutical market not only promotes the development of local pharmaceutical companies, but also creates a huge attraction for multinational pharmaceutical groups
.
According to ChinaBio's data, in 2020, multinational pharmaceutical groups such as Roche, Bayer, AbbVie, and Pfizer have reached a record 271 cross-border licensing cooperation agreements with Chinese pharmaceutical companies, an increase of nearly in 2019 and 2015 respectively.
50% and more than 300%
.
Judging from the current transaction situation in 2021, the cooperation between multinational giants and local pharmaceutical companies is still continuing the growth trend of 2020
.
It is worth mentioning that in addition to the continuous increase in the number of cooperation, from the perspective of the cooperation model of Chinese and foreign pharmaceutical companies, the two parties have also changed from the initial joint venture to set up factories to license cooperation around the research and development of innovative drugs, which means that local companies’ drugs Innovative research and development capabilities have also been recognized
.
The industry believes that with China’s promulgation of a series of drug approval procedures, intellectual property protection, tax reduction and exemption, and the introduction of talents, policies to encourage the promotion of the research and development, marketing and sales of innovative drugs
.
In the future, this innovative model of combining powerful forces will continue.
Affected by this, the market share of China's innovative drugs is expected to increase further
.
